Drugmakers, insurers, hospitals, pharmacies, medical devices, clinical updates, and healthcare business leaders.
A market recap highlights that, beyond Pfizer’s headline revenue and earnings figures for the quarter ended June 2026, investors are weighing how several underlying performance measures compared with Wall Street expectations.
THE APEX TIMES
THE APEX TIMES
For the quarter ended June 2026, Pfizer reported earnings and revenue that topped analyst estimates by 13.24% and 4.04%, according to a market wrap. The update adds momentum to a results season that hinges on how durable underlying demand and cost discipline remain.
THE APEX TIMES
The healthcare giant says its AI Learning Academy earned three honors at the 11th Annual Stevie Awards for Great Employers, highlighting the company’s focus on employee development.
THE APEX TIMES
The healthcare group said Executive Vice President Jennifer Taubert will retire and that Tom Cavanaugh will take over her role as Worldwide Chairman of Innovative Medicine, effective in September.
THE APEX TIMES
A steep decline in Pfizer’s Covid antiviral revenue weighed on expectations, yet the company’s reported earnings beat forecasts in the second quarter. A separate readout from its BioNTech vaccine partner highlighted weaker Covid demand.
THE APEX TIMES
The company boosted its full-year sales guidance by $500 million following stronger-than-expected results in the quarter.
THE APEX TIMES
The companies said they signed a Clinical Trial Collaboration and Supply Agreement to evaluate Amplia’s investigational FAK inhibitor narmafotinib in combination with Eli Lilly’s investigational KRAS G12C therapy olomorasib (marketed as Lumakras in the U.S.), in patients with non-small cell lung cancer.
THE APEX TIMES
Pfizer said second-quarter revenue grew 2.6% year over year to $15.03 billion, a result described by Yahoo Finance as beating Wall Street forecasts. The company also reiterated that it expects full-year revenue to grow, though the specific target was not detailed in the cited post.
THE APEX TIMES
The drugmaker says its Phase 3 trial data support moving toward global regulatory filings for LITFULO, an oral therapy aimed at the autoimmune skin condition vitiligo.
